Alendronate and naproxen are synergistic for development of gastric ulcers

被引:45
作者
Graham, DY
Malaty, HM
机构
[1] Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1001/archinte.161.1.107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Both alendronate sodium use and nonsteroidal anti-inflammatory drug use are associated with gastric ulcers. The aim of this study was to investigate whether alendronate and naproxen are synergistic as causes of gastric ulcers. Methods: We performed an endoscopist-blind, randomized, crossover, single-center comparison of 10 mg/d of alendronate sodium, 500 mg of naproxen sodium twice daily, or the combination taken orally for 10 days in volunteers aged 30 years or older. Videoendoscopy was used to evaluate the presence and degree of mucosal damage to the esophagus, stomach, or duodenal bulb before and after each treatment. There was a 1- to 4-week washout between evaluations. Results: Twenty-six healthy volunteers participated (18 women and 8 men), aged 30 to 50 years. Gastric ulcers were present in 2 subjects receiving alendronate (8%), in 3 receiving naproxen (12%), and in 10 receiving both (38%) (P<.05 for the combination vs either drug alone). Conclusions: Both alendronate and naproxen can cause gastric ulcers. The combination appears synergistic. Alendronate should be used with caution in those who simultaneously require nonsteroidal anti-inflammatory drugs.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 33 条
  • [1] Abdelmalek MF, 1996, AM J GASTROENTEROL, V91, P1282
  • [2] Abraham SC, 1999, MODERN PATHOL, V12, P1152
  • [3] EFFECTS OF 2 ORAL DOSES OF ALENDRONATE IN THE TREATMENT OF PAGETS-DISEASE OF BONE
    ADAMI, S
    MIAN, M
    GATTI, P
    ROSSINI, M
    ZAMBERLAN, N
    BERTOLDO, F
    LOCASCIO, V
    [J]. BONE, 1994, 15 (04) : 415 - 417
  • [4] Upper gastrointestinal tract safety profile of alendronate -: The Fracture Intervention Trial
    Bauer, DC
    Black, D
    Ensrud, K
    Thompson, D
    Hochberg, M
    Nevitt, M
    Musliner, T
    Freedholm, D
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) : 517 - 525
  • [5] Nonclinical model for assessing gastric effects of bisphosphonates
    Blank, MA
    Ems, BL
    Gibson, GW
    Myers, WR
    Berman, SK
    Phipps, RJ
    Smith, PN
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (02) : 281 - 288
  • [6] ''Pill esophagitis'' - The case of alendronate
    Castell, DO
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1058 - 1059
  • [7] Colina RE, 1997, AM J GASTROENTEROL, V92, P704
  • [8] Esophagitis associated with the use of alendronate
    deGroen, PC
    Lubbe, DF
    Hirsch, LJ
    Daifotis, A
    Stephenson, W
    Freedholm, D
    PryorTillotson, S
    Seleznick, MJ
    Pinkas, H
    Wang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1016 - 1021
  • [9] Ettinger B, 1998, AM J MANAG CARE, V4, P1377
  • [10] ORAL BISPHOSPHONATES IN THE TREATMENT OF OSTEOPOROSIS - A REVIEW
    FRANCIS, RM
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (09): : 831 - 851